STOCK TITAN

Oncology Institute holder reports 5.2% stake

Oncology Institute, Inc. reported that investor Jorey Chernett has filed a Schedule 13G disclosing a significant ownership position in the company’s common stock.

Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Oncology Institute, Inc. reported that investor Jorey Chernett has filed a Schedule 13G disclosing a significant ownership position in the company’s common stock. Chernett beneficially owns 5,114,944 shares of common stock, representing 5.2% of the class. All of these shares are reported with sole voting and sole dispositive power, with no shared voting or dispositive authority.

The filing indicates this is a passive investment. Chernett certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of Oncology Institute, Inc., and are not held in connection with any transaction intended to have that effect. The date of the ownership event triggering the filing is stated as January 14, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who filed the Schedule 13G for Oncology Institute, Inc. (TOI)?

The Schedule 13G was filed by Jorey Chernett as the reporting person and beneficial owner of a significant stake in Oncology Institute, Inc.

How many Oncology Institute, Inc. (TOI) shares does Jorey Chernett beneficially own?

Jorey Chernett beneficially owns 5,114,944 shares of Oncology Institute, Inc. common stock, according to the Schedule 13G.

What percentage of Oncology Institute, Inc. (TOI) is owned by Jorey Chernett?

The filing reports that Jorey Chernett’s 5,114,944 shares represent 5.2% of the outstanding common stock of Oncology Institute, Inc.

Does Jorey Chernett have sole or shared voting power over TOI shares?

The Schedule 13G states that Jorey Chernett has sole voting power and sole dispositive power over all 5,114,944 shares, with no shared voting or dispositive power.

Is the Oncology Institute, Inc. (TOI) stake held for control purposes?

No. Chernett certifies that the TOI shares were not acquired and are not held for the purpose of changing or influencing control of Oncology Institute, Inc.

When did the ownership event requiring this TOI Schedule 13G occur?

The date of the event that required this Schedule 13G filing is listed as January 14, 2026.

Is Jorey Chernett part of a group holding Oncology Institute, Inc. (TOI) shares?

No. The Schedule 13G indicates the ownership is reported individually, and the items on group membership and group dissolution are marked Not Applicable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Chernett Jorey
Signature:/s/Jorey Chernett
Name/Title:Individual
Date:01/15/2026

Keep reading